11.05.2011
Teva Pharmaceutical Industries, the world's largest generic drugmaker, met forecasts with a 14% rise in quarterly earnings on strong sales growth in Europe following last year's Ratiopharm acquisition.
Israel-based Teva, which last week announced a deal to acquire U.S. specialty drugmaker Cephalon for $6.8 billion, posted first-quarter earnings before certain items of $1.04 per share. Sales rose 12.1% to $4.1 billion.
more03.11.2010
Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, posted higher quarterly net profit that beat expectations, boosted by strong U.S. sales and its acquisition of Ratiopharm.
Third-quarter earnings per share excluding one-time items rose 46% to $1.30, Israel-based Teva said on Tuesday. Sales rose 20% to $4.25 billion.
more04.08.2010
Pharmaceutical firm Teva may go ahead with its €3.7 billion takeover of German generic drugmaker Ratiopharm if the companies divest products in the Netherlands and Hungary, the European Commission said on Wednesday.
more06.07.2010
Phoenix, Europe's second-largest drugs distributor, said on Monday it had secured its independence and a platform for growth by winning lenders' backing for a financial overhaul.
more05.05.2010
Teva Pharmaceutical Industries, the world's biggest generic drugmaker, said strong sales of its Copaxone drug and new generic products gave it a forecast-beating increase in adjusted net profit in the first quarter.
more29.03.2010
Germany unveiled plans to cut patented drug prices on Friday, hitting shares in major drugmakers, the latest sign that indebted governments intend to bear down on runaway medical costs.
more19.03.2010
Pfizer may still be eager to buy generic drugmakers, after being outbid for Germany's Ratiopharm in an effort to shore up revenue as it braces for evaporating sales of its blockbuster Lipitor cholesterol treatment.
more18.03.2010
Israel's Teva has won the battle for German generic drugmaker Ratiopharm, three sources said, fixing the industry leader's weakness in the world's second-largest generics market.
Teva, already the world's biggest maker of generic drugs, beat U.S. drugs powerhouse Pfizer and Iceland's Actavis in the race for Ratiopharm, agreeing to pay more than €3.5 billion including debt, two of the sources close to the situation said.
more18.03.2010
The tussle over German generic drugs maker Ratiopharm is drawing to a close as the three remaining contenders square off in the final round of bidding, sources close to the deal told Reuters on Wednesday. Pfizer was submit its bid on Wednesday, a person briefed on the matter said.
With an expected price tag of above €3 billion, Ratiopharm would be selling at roughly two times sales, below historical generic drugs M&A multiples of three to four, reflecting the tough market conditions in Germany, JP Morgan analyst Chris Schott said in a recent research note.
more17.03.2010
Pfizer will on Wednesday place an offer in the final round of bids for German generic drug maker Ratiopharm, a person briefed on the matter told Reuters on Wednesday.
Ratiopharm's remaining suitors, which also include Israel's Teva and smaller Icelandic peer Actavis, had been requested to make final bids on Thursday at the latest, several sources had previously said.
Officials at Pfizer were not immediately available for comment.
more